Development of a human-based in vitro model for assessing neuronal activity has been challenging due to limitations in complex burst organisation and network characteristics of commercially available human neurons. However, these limitations have now been overcome with recent advances in iPSC-derived neurons.
Cyprotex are at the forefront of this technology and are highly experienced in specialist analytical techniques such as microelectrode array (MEA) where interpretation of the data can be complex. The company has developed a robust screening platform utilising MEA in combination with a human co-culture model (CDI iCell human iPSC-derived glutamatergic neurons and human iPSC-derived astrocytes). By evaluating spike and burst characteristics of electrical response for a set of target-specific neurotoxins and seizurogenic compounds, the utility of the platform for neurotoxicity and neuropharmacology testing has been demonstrated.
This research was recently presented at the SPS Annual meeting in Berlin in September 2017. To learn more, please download our poster.